BCAL Diagnostics (ASX:BDX) Total Long-Term Assets: A$2.39 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is BCAL Diagnostics Total Long-Term Assets?

BCAL Diagnostics ASX:BDX -5.33% Total Long-Term Assets is A$2.39 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. BCAL Diagnostics's Total Long-Term Assets for the quarter that ended in Dec. 2025 was A$2.39 Mil.

BCAL Diagnostics Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for BCAL Diagnostics's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BCAL Diagnostics Total Long-Term Assets Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Total Long-Term Assets
0.08 2.10 2.93 2.71

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.09 2.93 3.03 2.71 2.39

BCAL Diagnostics Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of A$2.39 Mil mean?
BCAL Diagnostics (ASX:BDX) has a Total Long-Term Assets of A$2.39 Mil as of Dec. 2025. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on BCAL Diagnostics and its competitors.
Is BCAL Diagnostics' Total Long-Term Assets too high?
BCAL Diagnostics' current Total Long-Term Assets is A$2.39 Mil.
How does BCAL Diagnostics' Total Long-Term Assets compare to TMO and DHR?
BCAL Diagnostics' Total Long-Term Assets of A$2.39 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Medical Diagnostics & Research company?
A good Total Long-Term Assets depends on the Medical Diagnostics & Research industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on BCAL Diagnostics and its competitors. BCAL Diagnostics's current Total Long-Term Assets is A$2.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current Total Long-Term Assets of A$2.39 Mil. The current Total Long-Term Assets is A$2.39 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current Total Long-Term Assets is A$2.39 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BCAL Diagnostics Business Description

Address 50 Clarence Street, Suite 506, Level 5, Sydney, NSW, AUS, 2000
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.